RE:We’re now entering the visibility zoneVisibility to an audience (urologists) that can influence big pharmas interest.
The degree of interest and enthousiasm will translate into big pharmas rushing on us or not as it will translate in market penetration for them. And this, is what will dictate our valuation.
The fun begins.